Kyverna Therapeutics logo

Kyverna Therapeutics

KYTX | NASDAQ
Chart Builder DCF Calculator
$4.76
-$0.29 (-5.74%)
At close: Nov 16, 2026, 4:00 PM ET
$4.76
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.74%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
26.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #879/1021 (Top 86%)

Key Statistics

Market Data

Market Cap $300.94M
1D Range
4.74 5.05
52W Range
4.61 11.25

Valuation (TTM)

PE -1.72
PB 2.26
EV/EBITDA -1.06

Valuation (NTM)

Forward PE N/A
Forward PEG 0.07
Price Target $25.00
Loading financial charts...

Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous...

Sector Healthcare
Industry Biotechnology
Employees 149
IPO Date Feb 9, 2024
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Next Earnings
Apr 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$25.00
Upside
+425.21%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.